[go: up one dir, main page]

JP2011012003A - Emulsion composition for soft capsule and soft capsule - Google Patents

Emulsion composition for soft capsule and soft capsule Download PDF

Info

Publication number
JP2011012003A
JP2011012003A JP2009156744A JP2009156744A JP2011012003A JP 2011012003 A JP2011012003 A JP 2011012003A JP 2009156744 A JP2009156744 A JP 2009156744A JP 2009156744 A JP2009156744 A JP 2009156744A JP 2011012003 A JP2011012003 A JP 2011012003A
Authority
JP
Japan
Prior art keywords
soft capsule
polyhydric alcohol
emulsifier
composition
emulsified composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009156744A
Other languages
Japanese (ja)
Other versions
JP5421674B2 (en
Inventor
Yoichi Orihara
洋一 折原
Hiroyuki Sakaguchi
博之 阪口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fancl Corp
Original Assignee
Fancl Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fancl Corp filed Critical Fancl Corp
Priority to JP2009156744A priority Critical patent/JP5421674B2/en
Publication of JP2011012003A publication Critical patent/JP2011012003A/en
Application granted granted Critical
Publication of JP5421674B2 publication Critical patent/JP5421674B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

【課題】多量に乳化剤を用いることなく、油性成分を高比率とするソフトカプセル製剤用乳化組成物を開発する
【解決手段】油性成分(A)、多価アルコール(B)、乳化剤(C)を含有するソフトカプセル製剤用乳化組成物であって、多価アルコール(B)が無水状態で液状の多価アルコール(B−1)と固体状の多価アルコール(B−2)を含有し、B−1とB−2の比が、1:3〜1:6であるソフトカプセル製剤用乳化組成物。
【選択図】なし
[PROBLEMS] To develop an emulsified composition for a soft capsule formulation with a high ratio of oily components without using a large amount of emulsifier. [Solution] Contains oily component (A), polyhydric alcohol (B), and emulsifier (C) An emulsified composition for a soft capsule formulation, wherein the polyhydric alcohol (B) is in an anhydrous state and contains a liquid polyhydric alcohol (B-1) and a solid polyhydric alcohol (B-2), and B-1. The emulsified composition for soft capsule formulation whose ratio of B-2 is 1: 3 to 1: 6.
[Selection figure] None

Description

本発明は自己乳化能を有するソフトカプセル製剤用組成物に関するものである。   The present invention relates to a composition for a soft capsule preparation having self-emulsifying ability.

自己乳化とは自然乳化とも呼ばれる現象で、水もしくは消化液に触れることで外力を必要とすることなく自然に乳化する現象のことを指す。この現象を利用した製剤として自己乳化型製剤(SEDDS)が知られている。この技術を導入することで、胆汁酸による乳化工程を経なくても、乳化することから食前・食後を問わず吸収されやすくなると言われている。
水に対して難溶性の生理活性成分を含む健康食品、医薬品ないし医薬部外品等においては、生理活性成分の吸収率の改善が課題となっており、これまで難溶性生理活性成分の吸収性改善を目的として生理活性成分の微細化や、乳化剤添加による難溶性生理活性成分の溶解性改善が試みられている。
Self-emulsification is a phenomenon called natural emulsification, and refers to a phenomenon of natural emulsification by touching water or digestive fluid without requiring external force. A self-emulsifying formulation (SEDDS) is known as a formulation utilizing this phenomenon. By introducing this technique, it is said that even if it does not go through an emulsification step with bile acid, it is emulsified and easily absorbed either before or after a meal.
In health foods, pharmaceuticals or quasi-drugs that contain poorly water-soluble physiologically active ingredients, improvement of the absorption rate of physiologically active ingredients has been an issue. For the purpose of improvement, attempts have been made to refine physiologically active ingredients and improve the solubility of hardly soluble physiologically active ingredients by adding an emulsifier.

特に近年コエンザイムQ10のように高い生理活性を持ちながらも、難水溶性物質であるために吸収されにくいような生理活性成分については、該生理活性成分を含む製剤中に1種または2種以上の乳化剤と、それらを溶解させるための助溶媒等を添加することで、空腹時に摂取したとしても、水もしくは消化液と接触するだけで自然に乳化・分散するように工夫された製剤が着目されている。このような製剤は、ソフトカプセルなどのカプセル剤型とすると取扱いや摂取に適している。
このような技術を健康食品、医薬品、医薬部外品などの経口摂取用の製剤に応用する場合には、乳化剤の使用量が多く、消化管の炎症をもたらしたり、吸収後細胞にダメージを与える可能性もある。また乳化剤の使用量が多いことは消費者にとっての心象も良くないことから出来る限り使用量を少なくすることが望ましい。乳化剤が多いことは相対的に油剤量が少なくなり、1カプセルに含まれる油剤に溶解している生理活性成分が少ないことになる。
例えば、特許文献1には、油性溶媒(乳化剤)としてデカグリセリルペンタオレートをコエンザイムQ10の12.5〜13.5倍量用い、安定化剤(補助界面活性剤)としてジアシルモノカプリン酸をコエンザイムQ10の0.4〜1.6倍量配合してなる自己乳化型軟カプセルの例が開示されている。この結果、自己乳化型軟カプセルには、コエンザイムQ10に対して12.9〜15.1倍の乳化剤が必要となっている。
非特許文献1には、このような乳化剤高濃度使用に伴う潜在的毒性を避ける目的で、最小量(3%)の乳化剤使用に基づく新しい乳化製剤の例が提示されている。しかしながら、使用している乳化剤はポリオキシエチレンアルキルエーテルであり、また助溶媒にはポリエチレングリコールが使用されていることから、食品添加剤としては適さず健康食品などの加工食品へ使用することは出来ない。
In particular, with regard to bioactive ingredients that have high bioactivity, such as coenzyme Q10, but are difficult to be absorbed because they are poorly water-soluble substances, one or more of them are included in the preparation containing the bioactive ingredient. By adding emulsifiers and co-solvents to dissolve them, even when ingested on an empty stomach, attention has been paid to preparations that are devised to spontaneously emulsify and disperse only by contact with water or digestive fluid Yes. Such a preparation is suitable for handling and ingestion if it is a capsule type such as a soft capsule.
When applying such technology to preparations for oral intake such as health foods, pharmaceuticals, and quasi drugs, the amount of emulsifier used is large, causing inflammation of the gastrointestinal tract and damaging cells after absorption. There is a possibility. Moreover, since it is not good for consumers to use a large amount of emulsifier, it is desirable to reduce the amount used as much as possible. When the amount of the emulsifier is large, the amount of the oil agent is relatively small, and the physiologically active ingredient dissolved in the oil agent contained in one capsule is small.
For example, Patent Document 1 uses decaglyceryl pentaoleate as an oily solvent (emulsifier) in an amount 12.5 to 13.5 times that of coenzyme Q10, and diacyl monocapric acid as a stabilizer (co-surfactant) 0.4 to 1.6 of coenzyme Q10. An example of a self-emulsifying soft capsule containing a double amount is disclosed. As a result, self-emulsifying soft capsules require 12.9 to 15.1 times as much emulsifier as Coenzyme Q10.
Non-Patent Document 1 provides an example of a new emulsified preparation based on the use of a minimum amount (3%) of an emulsifier in order to avoid the potential toxicity associated with the use of such a high concentration of emulsifier. However, since the emulsifier used is polyoxyethylene alkyl ether and polyethylene glycol is used as a co-solvent, it is not suitable as a food additive and can be used for processed foods such as health foods. Absent.

一方、健康食品用途における自己乳化製剤の課題は、多量の乳化剤使用の外に、助溶媒にもある。非特許文献2には現在実用化されている自己乳化製剤の例が取り上げられており、その中で多量の乳化剤もしくは生理活性成分を溶解させるための助溶媒としてエタノール、プロピレングリコール、ポリエチレングリコールなどの溶媒が適しているとしている。
しかしながら、該組成物中の助溶媒はカプセル皮膜へ移行してしまい、組成物から生理活性成分が析出して分離してしまう課題があるとしている。また助溶媒のカプセル皮膜への移行はカプセルの軟化も引き起こし、カプセルの変形を生じさせてしまうこともある。カプセル皮膜は消化器官内で溶ける材質である水溶性成分であるので、封入される成分中の水分がカプセル皮膜に作用してカプセルの変形や崩壊が発生する危険がある。水分によるソフトカプセルの変形などの課題を克服することもソフトカプセル充填剤としては重要な要因である(特許文献2)。
したがって、カプセル剤型は、1個のカプセル内に多くの生理活性成分を封入する場合には、その生理活性成分の溶媒となる油剤の比率を高くすることが望ましく、カプセルに封入される成分中の水溶性成分の皮膜を変形するなどの影響を小さくすることが好ましい。
On the other hand, the problem of self-emulsifying preparations for health food applications lies in cosolvents in addition to the use of a large amount of emulsifiers. Non-Patent Document 2 describes examples of self-emulsifying preparations currently in practical use. Among them, ethanol, propylene glycol, polyethylene glycol and the like are used as cosolvents for dissolving a large amount of emulsifiers or physiologically active ingredients. The solvent is said to be suitable.
However, the cosolvent in the composition is transferred to the capsule film, and there is a problem that a physiologically active component is precipitated and separated from the composition. In addition, the transfer of the cosolvent to the capsule film also causes softening of the capsule, which may cause deformation of the capsule. Since the capsule film is a water-soluble component that is a material that dissolves in the digestive organs, there is a risk that the moisture in the encapsulated component acts on the capsule film to cause deformation or collapse of the capsule. Overcoming problems such as deformation of soft capsules due to moisture is also an important factor for soft capsule fillers (Patent Document 2).
Therefore, in the capsule type, when many physiologically active ingredients are encapsulated in one capsule, it is desirable to increase the ratio of the oil agent serving as a solvent for the physiologically active ingredient. It is preferable to reduce the influence of deformation of the water-soluble component film.

また特許文献3には、5〜30%重量部の脂溶性物質(有効成分)、5〜30%重量部の乳化剤、30〜85%重量部の多価アルコール、水を混合した脂溶性物質の水溶液剤が開示されている。実施例では多価アルコールとしてD−ソルビトール水飴、グリセリンを用いた例が挙げられているが、これらは乳化剤、多価アルコールの使用量が多いため、脂溶性物質(有効成分)を多く配合することができない。具体的な用途は、ドリンク剤などがあげられており、水分量も多いのでソフトカプセルには適さない配合である。
またカプセルに充填後、安定性を担保できるかについても不明であるが、これと類似した事例として、特許文献4の比較例4に乳化剤としてショ糖脂肪酸エステル3%、多価アルコール相としてグリセリン57%、水10%、油性成分として中鎖トリグリセライドの組み合わせの例が挙げられている。しかし、40℃環境でカプセルを保管したところ、2週間で変形が始まり、4週間で大きな変形を伴ったと記載されている。
特許文献5には、10重量%のコエンザイムQ10、35重量%の油相成分、50重量%の多価アルコール及び5重量%の乳化剤を含有する乳化組成物を含有したソフトカプセルが開示されている。実施例14に優れた分散を示すソフトカプセルの例が開示されている。
Patent Document 3 discloses a fat-soluble substance in which 5 to 30% by weight of a fat-soluble substance (active ingredient), 5 to 30% by weight of an emulsifier, 30 to 85% by weight of a polyhydric alcohol, and water are mixed. An aqueous solution is disclosed. In the examples, D-sorbitol starch syrup and glycerin are used as polyhydric alcohols. However, since these use large amounts of emulsifiers and polyhydric alcohols, a large amount of fat-soluble substances (active ingredients) should be added. I can't. Specific applications include drinks and the like, and the amount of water is large, so that the formulation is not suitable for soft capsules.
It is also unclear whether the capsule can be secured after filling, but as a similar example, in Comparative Example 4 of Patent Document 4, sucrose fatty acid ester 3% as an emulsifier and glycerin 57 as a polyhydric alcohol phase. %, 10% water, and examples of combinations of medium chain triglycerides as oil components. However, it is described that when the capsule was stored in a 40 ° C. environment, the deformation started in 2 weeks and accompanied by a large deformation in 4 weeks.
Patent Document 5 discloses a soft capsule containing an emulsified composition containing 10% by weight of coenzyme Q10, 35% by weight of an oil phase component, 50% by weight of a polyhydric alcohol and 5% by weight of an emulsifier. An example of a soft capsule showing excellent dispersion is disclosed in Example 14.

特開昭62−67019号公報JP-A 62-67019 特開2005−60252号公報JP 2005-60252 A 特許第3880265号Patent No. 3880265 特開2005−60252号公報JP 2005-60252 A 特開2003−238396号公報JP 2003-238396 A

Chem. Pharm. Bull. 46(2) 309-313 (1998)Chem. Pharm. Bull. 46 (2) 309-313 (1998) Biomedicine & Pharmacotherapy 58 (2004) 173-182Biomedicine & Pharmacotherapy 58 (2004) 173-182

本発明は、多量に乳化剤を用いることなく、油性成分を高比率とするソフトカプセル製剤用乳化組成物を開発することを目的とする。   An object of this invention is to develop the emulsification composition for soft capsule formulations which makes an oil-based component a high ratio, without using an emulsifier in large quantities.

本発明者らは、上記課題解決のため鋭意研究した結果、無水状態で液体の多価アルコールと無水状態で固体の多価アルコールを混合させたものの中に乳化剤共存させたものを外相、油相成分を内相とする水溶性の乳化組成物を調製することで、従来型の自己乳化製剤よりも油相成分高配合で乳化剤使用量を大幅に低減させた製剤を得られることを見出した。また該組成物中に含まれる多価アルコールは無水状態での液体のものと無水状態で個体のものをある特定の比率の範囲で含んでいる場合においてのみ、ソフトカプセル充填が可能で、ソフトカプセル充填後も自己乳化性を維持でき、尚且つソフトカプセル皮膜への多価アルコール移行を抑制し、該組成物が分離することなく安定で、カプセルの軟化、変形を抑制できるという知見を得て本発明に至った。
また油性成分を高比率にするために使用する乳化剤としては多価アルコール、油性成分間で強固な界面膜を作るものが望ましい。具体的には多価アルコールおよび油性成分に対して易溶ではなく、常温かつ脱水・脱油状態で固体状のものが望ましい。具体的にはリゾレシチンが望ましく、リゾレシチン中に含まれるリゾホスファチジルコリン濃度が少なくとも18%以上、望ましくは65%以上含まれているものがソフトカプセルへ充填した時の長期安定性の面から望ましい。またリゾホスファチジルコリンをリゾホスホリパーゼDによりコリンを除去したリゾホスファチジン酸も本発明の乳化剤として使用できる。リゾレシチンの他に、食品用乳化剤として汎用的に用いられているものとしては、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステルなどが挙げられるが、これらは多価アルコールあるいは油性成分に対して易溶であり、界面膜を作るためにはリゾレシチンに比べると多量の乳化剤添加を必要とすることから適していない。また常温で固体状の乳化剤としてはショ糖脂肪酸エステルが挙げられ、こちらについてもリゾレシチン同様の作用が確認されたが、リゾレシチンを用いた場合よりも油性成分を高配合にすることは出来なかった。
As a result of diligent research for solving the above problems, the present inventors have obtained an outer phase, an oil phase, and an oil phase in which an emulsifier coexists in a mixture of a polyhydric alcohol that is liquid in an anhydrous state and a solid polyhydric alcohol that is anhydrous. It has been found that by preparing a water-soluble emulsified composition having an ingredient as an internal phase, it is possible to obtain a preparation in which the amount of emulsifier used is greatly reduced with a higher blend of oil phase components than conventional self-emulsifying preparations. In addition, the polyhydric alcohol contained in the composition can be filled with a soft capsule only when it contains a liquid in an anhydrous state and an individual in an anhydrous state in a certain ratio range. Obtained the knowledge that it can maintain the self-emulsifying property, suppress the migration of polyhydric alcohol to the soft capsule film, is stable without separation, and can suppress the softening and deformation of the capsule. It was.
Moreover, as an emulsifier used in order to make an oily component into a high ratio, what makes a firm interface film between a polyhydric alcohol and an oily component is desirable. Specifically, it is desirable that it is not readily soluble in polyhydric alcohols and oily components but is solid at room temperature and in a dehydrated / deoiled state. Specifically, lysolecithin is preferable, and lysophosphatidylcholine concentration contained in lysolecithin is preferably at least 18% or more, preferably 65% or more from the viewpoint of long-term stability when filled into a soft capsule. Moreover, lysophosphatidic acid obtained by removing choline from lysophosphatidylcholine with lysophospholipase D can also be used as an emulsifier of the present invention. In addition to lysolecithin, those commonly used as food emulsifiers include glycerin fatty acid esters, polyglycerin fatty acid esters, etc., but these are readily soluble in polyhydric alcohols or oil components, In order to make an interface film, a large amount of an emulsifier needs to be added compared to lysolecithin, which is not suitable. Moreover, sucrose fatty acid ester is mentioned as a solid-state emulsifier at normal temperature, The action similar to lysolecithin was confirmed here, However, The oil component was not able to be made highly mixed rather than the case where lysolecithin was used.

本発明の主な構成は次のとおりである。
(1)油性成分(A)、多価アルコール(B)、乳化剤(C)を含有するソフトカプセル製剤用乳化組成物であって、
多価アルコール(B)が無水状態で液状の多価アルコール(B−1)と固体状の多価アルコール(B−2)を含有し、B−1とB−2の比が、1:3〜1:6であることを特徴とするソフトカプセル製剤用乳化組成物。
(2)水を除く組成物中の多価アルコール(B)が15〜25%重量、乳化剤(C)が2.0%重量以下、油性成分(A)が65.0〜80.0%重量であることを特徴とする(1)記載のソフトカプセル製剤用乳化組成物。
(3)油性成分(A)が中鎖脂肪酸トリグリセライドまたは動植物性オイルであり、当該油性成分に可溶な脂溶性物質(D)を含む(1)又は(2)記載のソフトカプセル製剤用乳化組成物。
(4)多価アルコールB−1がグリセリンであることを特徴とする(1)〜(3)のいずれかに記載のソフトカプセル製剤用乳化組成物。
(5)多価アルコールB−2がD-ソルビトール及び/又は還元澱粉糖化物であることを特徴とする(1)〜(4)のいずれかに記載のソフトカプセル製剤用乳化組成物。
(6)乳化剤(C)がリゾレシチンであり、原料中に含まれるリゾホスファチジルコリンの濃度が少なくとも18%以上、望ましくは65%以上であることを特徴とする(1)〜(5)のいずれかに記載のソフトカプセル製剤用乳化組成物。
(7)油性成分に可溶な脂溶性物質(D)が、コエンザイムQ10、還元型コエンザイムQ10、リポ酸、α、β-、γ-δ-トコフェロール、α、β-、γ-δ-トコトリエノール、α、β-、γ-δ-カロテン、リコペン、ルテイン、ゼアキサンチン、アスタキサンチン、ビタミンD、ビタミンA、ビタミンP、DHA、EPA、スクワランから選ばれる少なくとも1種または2種以上を含むことを特徴とする(1)〜(6)のいずれかに記載のソフトカプセル製剤用乳化組成物。
(8)(1)〜(7)のいずれかに記載されたソフトカプセル製剤用乳化組成物を封入したソフトカプセル製剤。
(9)ソフトカプセル封入前の水が10重量%以下であり、カプセルに封入後、内溶液中に含まれる水を乾燥工程で5%以下にしたことを特徴とする(1)〜(7)のいずれかに記載されたソフトカプセル製剤用乳化組成物を封入したソフトカプセル製剤。
(10)油性成分(A)、多価アルコール(B)、乳化剤(C)を含有するソフトカプセル製剤用乳化組成物であって、多価アルコール(B)が無水状態で液状の多価アルコール(B−1)と固体状の多価アルコール(B−2)を含有し、B−1とB−2の比が、1:3〜1:6であるソフトカプセル製剤用乳化組成物を調整する方法であって、
乳化剤(C)を多価アルコール(B)に溶かし込み、次いで、均質に攪拌しつつ油性成分(A)を徐々に加えて高粘性ゲルを調製し、脱泡してソフトカプセル製剤用乳化組成物を調整する方法。
The main configuration of the present invention is as follows.
(1) An emulsified composition for a soft capsule formulation containing an oily component (A), a polyhydric alcohol (B), and an emulsifier (C),
The polyhydric alcohol (B) contains a liquid polyhydric alcohol (B-1) and a solid polyhydric alcohol (B-2) in an anhydrous state, and the ratio of B-1 to B-2 is 1: 3. An emulsified composition for soft capsule preparations, characterized in that it is ˜1: 6.
(2) The polyhydric alcohol (B) in the composition excluding water is 15 to 25% by weight, the emulsifier (C) is 2.0% by weight or less, and the oil component (A) is 65.0 to 80.0% by weight. The emulsified composition for soft capsule preparation according to (1).
(3) The emulsified composition for soft capsule preparation according to (1) or (2), wherein the oily component (A) is a medium-chain fatty acid triglyceride or animal and vegetable oil and contains a fat-soluble substance (D) soluble in the oily component .
(4) The emulsion composition for soft capsule formulations according to any one of (1) to (3), wherein the polyhydric alcohol B-1 is glycerin.
(5) The emulsion composition for soft capsule preparations according to any one of (1) to (4), wherein the polyhydric alcohol B-2 is D-sorbitol and / or a reduced starch saccharified product.
(6) The emulsifier (C) is lysolecithin, and the concentration of lysophosphatidylcholine contained in the raw material is at least 18% or more, preferably 65% or more, and any one of (1) to (5) The emulsified composition for soft capsule formulation as described.
(7) The fat-soluble substance (D) soluble in the oil component is coenzyme Q10, reduced coenzyme Q10, lipoic acid, α, β-, γ-δ-tocopherol, α, β-, γ-δ-tocotrienol, It contains at least one or more selected from α, β-, γ-δ-carotene, lycopene, lutein, zeaxanthin, astaxanthin, vitamin D, vitamin A, vitamin P, DHA, EPA, and squalane. (1) -Emulsion composition for soft capsule formulation in any one of (6).
(8) A soft capsule preparation encapsulating the emulsified composition for a soft capsule preparation described in any one of (1) to (7).
(9) The water before soft capsule encapsulation is 10% by weight or less, and after encapsulating in the capsule, the water contained in the inner solution is 5% or less in the drying step, (1) to (7) The soft capsule formulation which enclosed the emulsified composition for soft capsule formulations described in any one.
(10) An emulsified composition for a soft capsule formulation comprising an oily component (A), a polyhydric alcohol (B), and an emulsifier (C), wherein the polyhydric alcohol (B) is a liquid polyhydric alcohol (B) in an anhydrous state -1) and a solid polyhydric alcohol (B-2), wherein the ratio of B-1 to B-2 is 1: 3 to 1: 6. There,
The emulsifier (C) is dissolved in the polyhydric alcohol (B), and then the oily component (A) is gradually added while stirring uniformly to prepare a highly viscous gel, which is defoamed to obtain an emulsified composition for a soft capsule formulation. How to adjust.

本発明は、高い油性成分比率(特に、65.0%以上)であって、多量に乳化剤を用いることなく、水もしくは消化液と接触すると速やかに乳化・分散する自己乳化組成物を提供することができる。本発明の自己乳化組成物をソフトカプセルに充填しても、自己乳化組成物が分離することなく安定で、ソフトカプセルの軟化、変形も生じない組成物を提供することができる。
本発明の自己乳化組成物は、乳化剤を多価アルコールに予め溶かし込み、次いで、均質に攪拌しつつ油性成分を徐々に加えることにより高粘性ゲルを調製し、脱泡して本発明のソフトカプセル用の自己乳化組成物とする。多価アルコールは、水分散性を維持するために必要であって、自己乳化性を担保するために一定の量を配合する必要がある。
The present invention can provide a self-emulsifying composition that has a high oil component ratio (especially 65.0% or more) and can quickly emulsify and disperse when contacted with water or digestive fluid without using a large amount of emulsifier. . Even when the self-emulsifying composition of the present invention is filled in a soft capsule, the self-emulsifying composition is stable without separation, and a soft capsule that does not soften or deform can be provided.
The self-emulsifying composition of the present invention is prepared by pre-dissolving an emulsifier in a polyhydric alcohol and then gradually adding an oil component while stirring uniformly to prepare a highly viscous gel and defoaming it for the soft capsule of the present invention. The self-emulsifying composition. The polyhydric alcohol is necessary to maintain water dispersibility, and a certain amount needs to be blended in order to ensure self-emulsification.

本発明の乳化組成物は、水もしくは消化液と接触すると速やかに乳化・分散する組成物を得ることができ、難水溶性物質の吸収性改善が期待される。本発明の乳化組成物は、乳化剤配合量が少なくて済み、油性成分比率が高くなる分、生理活性物質などの脂溶性有効成分を多く封入したソフトカプセルを提供することが可能である。
その他、本発明の自己乳化組成物は、乳化剤量が2%以下と少ない。保管中に60℃程度の高温になっても薬液中から油性成分が分離せず、熱安定性、保管性が高く。得られる組成物自身が比較的高粘性液体であるため、従来ソフトカプセルに用いられてきたミツロウやライスワックスのような動植物性ワックス(分散剤)を使用する必要がない。リゾレシチンは、天然系乳化剤であるから人工の乳化剤(界面活性剤)を含まないソフトカプセル用自己乳化組成物を提供することができる。
本発明の乳化組成物は、油相成分に溶解する健康食品、医薬品、医薬部外品、化粧品に通常使用される脂溶性物質を配合することが出来る。さらに耐熱性もあり、油性成分が分離しにくいことから熱処理に対しても安定である。
そして本発明は、上記したところから得られた乳化組成物をカプセルに充填して得られるソフトカプセル製剤並びにこれらを含む健康食品、医薬品、医薬部外品、化粧品に関する。
The emulsified composition of the present invention can provide a composition that quickly emulsifies and disperses when contacted with water or digestive fluid, and is expected to improve the absorbability of poorly water-soluble substances. The emulsified composition of the present invention requires only a small amount of the emulsifier and can provide a soft capsule in which a large amount of a fat-soluble active ingredient such as a physiologically active substance is encapsulated.
In addition, the self-emulsifying composition of the present invention has a small amount of emulsifier of 2% or less. Oily components are not separated from the chemicals even when the temperature rises to around 60 ° C during storage, and heat stability and storage are high. Since the resulting composition itself is a relatively high-viscosity liquid, it is not necessary to use an animal or vegetable wax (dispersant) such as beeswax or rice wax that has been used in soft capsules. Since lysolecithin is a natural emulsifier, it can provide a self-emulsifying composition for soft capsules that does not contain an artificial emulsifier (surfactant).
The emulsified composition of the present invention can contain a fat-soluble substance that is usually used in health foods, pharmaceuticals, quasi drugs, and cosmetics that are soluble in the oil phase component. Furthermore, it has heat resistance and is stable against heat treatment because it is difficult to separate oil components.
And this invention relates to the soft capsule formulation obtained by filling a capsule with the emulsified composition obtained from the above, and the health food, pharmaceutical, quasi-drug, and cosmetics containing these.

<本発明の概略>
本発明は、油性成分、多価アルコール、乳化剤からなる乳化組成物であり、乳化剤使用量の低減、多価アルコール配合量の低減、油性成分配合量の増加を実現しながら、同時にソフトカプセル皮膜の軟化・変形を抑制することができるソフトカプセル製剤用乳化組成物に関するものである。本発明の乳化組成物の必須構成は、油性成分(A)、液状と固体状の2種類の多価アルコール(B)、および、乳化剤(C)であって、ソフトカプセル製剤用乳化組成物に適する。各成分の配合は、油相成分(A)が65.0〜80.0%重量、多価アルコール(B)が15〜25%重量、乳化剤(C)が2.0%重量以下であることが望ましい。多価アルコール(B)は、無水状態で液状の多価アルコール(B−1)と固体状の多価アルコール(B−2)を同時に含有し、B−1とB−2の比が、1:3〜1:6であること重要である。
<Outline of the present invention>
The present invention is an emulsified composition comprising an oily component, a polyhydric alcohol, and an emulsifier, and at the same time softening the soft capsule film while realizing a reduction in the amount of emulsifier used, a reduction in the amount of polyhydric alcohol, and an increase in the amount of oily component. -It is related with the emulsion composition for soft capsule formulations which can suppress a deformation | transformation. The essential components of the emulsified composition of the present invention are an oily component (A), two kinds of polyhydric alcohols (B), liquid and solid, and an emulsifier (C), which are suitable for an emulsified composition for soft capsule formulations. . The blending of each component is desirably 65.0 to 80.0% by weight of the oil phase component (A), 15 to 25% by weight of the polyhydric alcohol (B), and 2.0% by weight or less of the emulsifier (C). The polyhydric alcohol (B) simultaneously contains a liquid polyhydric alcohol (B-1) and a solid polyhydric alcohol (B-2) in an anhydrous state, and the ratio of B-1 and B-2 is 1 : 3 to 1: 6 is important.

成分(A)
成分(A)、即ち油相成分としては、動植物性オイル、例えば大豆油、菜種油、綿実油、ひまわり油、サフラワー油、やし油、小麦胚芽油、コーン胚芽油、オリーブ油、米ぬか油、肝油、魚油、鯨油、中鎖脂肪酸トリグリセライドなどが挙げられる。これらの油相成分は、単独で、または2種以上組み合わせて用いても良い。実施例では脂肪酸組成中DHAを46%含有する魚油とコエンザイムQ10を溶解させた中鎖脂肪酸トリグリセライドを主に使用した。油相成分(A)は65.0〜80.0%重量が好ましい。
また、これらの動植物性オイルに溶解する脂溶性物質(D)として加えても良い。
Ingredient (A)
Ingredient (A), that is, the oil phase component includes animal and vegetable oils such as soybean oil, rapeseed oil, cottonseed oil, sunflower oil, safflower oil, palm oil, wheat germ oil, corn germ oil, olive oil, rice bran oil, liver oil, Examples include fish oil, whale oil, and medium chain fatty acid triglycerides. These oil phase components may be used alone or in combination of two or more. In the Examples, fish oil containing 46% of DHA in the fatty acid composition and medium chain fatty acid triglyceride in which coenzyme Q10 was dissolved were mainly used. The oil phase component (A) is preferably 65.0 to 80.0% by weight.
Moreover, you may add as a fat-soluble substance (D) which melt | dissolves in these animal and vegetable oils.

成分(B)
成分Bは、多価アルコールである。多価アルコールは、水分量を除き多価アルコール(B)の配合量は15〜25%重量が好ましい。
多価アルコール(B)が無水状態で液状の多価アルコール(B−1)と固体状の多価アルコール(B−2)を同時に含有し、B−1とB−2の比が、1:3〜1:6であることが好ましい。
特に、成分B−1としてグリセリンが適しており、特に濃グリセリンが望ましい。濃グリセリンとしては日本薬局方に収載されている規格(多価アルコール含量98.0〜101.0%)を満たすものを指すが、食品添加物公定書で定められている規格(グリセリン含量95.0%以上)のものでも構わない。グリセリンは水分量を除き、5.0%重量以下が好ましい。
成分B−2としては、ソルビトールが好ましい。本発明に当たっては粉末(固形状)および、水分40%以下で予め加水して液状にしたものを使用することが出来る。
ソルビトールは水分量を除き、固形換算で14〜23%重量が好ましい。
Ingredient (B)
Component B is a polyhydric alcohol. In the polyhydric alcohol, the blending amount of the polyhydric alcohol (B) is preferably 15 to 25% by weight excluding the amount of water.
The polyhydric alcohol (B) contains the liquid polyhydric alcohol (B-1) and the solid polyhydric alcohol (B-2) simultaneously in an anhydrous state, and the ratio of B-1 and B-2 is 1: It is preferably 3 to 1: 6.
In particular, glycerin is suitable as component B-1, and concentrated glycerin is particularly desirable. Concentrated glycerin refers to those that meet the standards (polyhydric alcohol content 98.0 to 101.0%) listed in the Japanese Pharmacopoeia, but those that are stipulated in the Food Additives Standard (glycerin content 95.0% or more) It doesn't matter. The glycerin is preferably 5.0% by weight or less, excluding the amount of water.
As component B-2, sorbitol is preferred. In the present invention, it is possible to use a powder (solid form) and a liquid that has been previously hydrated with a water content of 40% or less.
Sorbitol is preferably 14 to 23% by weight in terms of solid, excluding the amount of water.

成分(C)
成分Cは、乳化剤である。乳化剤は、水分量を除き配合量は2.0%重量以下が好ましい。
成分(D)として用いることができるリゾレシチンについては、原料中に含まれるリゾホスファチジルコリンの濃度が少なくとも18%以上であり、望ましくは65%以上のものが好ましい。
またリゾホスファチジルコリンをリゾホスホリパーゼDによりコリンを除去したリゾホスファチジン酸もリゾホスファチジルコリンと同等の濃度域で乳化剤として使用できる。
Ingredient (C)
Component C is an emulsifier. The amount of the emulsifier is preferably 2.0% by weight or less, excluding the amount of water.
Regarding the lysolecithin that can be used as the component (D), the concentration of lysophosphatidylcholine contained in the raw material is at least 18% or more, desirably 65% or more.
In addition, lysophosphatidic acid obtained by removing lysophosphatidylcholine from lysophosphatidylcholine with lysophospholipase D can also be used as an emulsifier in the same concentration range as lysophosphatidylcholine.

本発明のソフトカプセル製剤用の乳化組成物の各構成比は、油相成分(A)が65.0〜80.0%重量、多価アルコール(B)が15〜25%重量、乳化剤(C)が2.0%重量以下が好ましい。   The constituent ratios of the emulsified composition for the soft capsule preparation of the present invention are as follows: the oil phase component (A) is 65.0 to 80.0% by weight, the polyhydric alcohol (B) is 15 to 25% by weight, and the emulsifier (C) is 2.0% by weight. The following is preferred.

脂溶性物質(D)
本発明の乳化組成物の油相成分(A)には、非水溶性の生理活性物質などの脂溶性有効成分(D)を溶解することができる。脂溶性物質としては例えば、コエンザイムQ10、還元型コエンザイムQ10、リポ酸、α、β-、γ-δ-トコフェロール、α、β-、γ-δ-トコトリエノール、α、β-、γ-δ-カロテン、リコペン、ルテイン、ゼアキサンチン、アスタキサンチン、ビタミンD、ビタミンA、ビタミンP、DHA、EPA、スクワランなどが挙げられる。これらの脂溶性物質は、油性成分比率に応じて高充填でき、生理活性物質を多く封入したソフトカプセル剤を提供することが可能となる。
Fat-soluble substance (D)
A fat-soluble active ingredient (D) such as a water-insoluble physiologically active substance can be dissolved in the oil phase ingredient (A) of the emulsion composition of the present invention. Examples of the fat-soluble substances include coenzyme Q10, reduced coenzyme Q10, lipoic acid, α, β-, γ-δ-tocopherol, α, β-, γ-δ-tocotrienol, α, β-, γ-δ-carotene. Lycopene, lutein, zeaxanthin, astaxanthin, vitamin D, vitamin A, vitamin P, DHA, EPA, squalane and the like. These fat-soluble substances can be highly filled in accordance with the ratio of the oil component, and it is possible to provide a soft capsule encapsulating a large amount of physiologically active substance.

その他成分
得られる組成物自身がソフトカプセル充填に適する高粘性液体であるため、従来のソフトカプセル用乳化組成物に配合されていた、ミツロウなどの増粘剤、動植物性ワックス(分散剤)の使用の必要性が無くなり、あるいは使用する場合でも極力少なくすることができる。また、内溶液中の水分活性が高く、内容物への安定性が損なわれる場合には水分活性抑性剤としてベタインやアミノ酸であるグリシン、L−プロリンなどを1〜5%重量添加することも出来る。
Other ingredients The resulting composition itself is a highly viscous liquid suitable for soft capsule filling, so it is necessary to use thickeners such as beeswax and animal and vegetable waxes (dispersants) that have been blended in conventional emulsion compositions for soft capsules. Even if it is lost or used, it can be reduced as much as possible. In addition, when the water activity in the internal solution is high and the stability to the contents is impaired, betaine, amino acid glycine, L-proline, etc. may be added by 1 to 5% by weight as a water activity inhibitor. I can do it.

本発明の乳化組成物の製造方法
次に、本発明の乳化組成物の製造方法について説明する。
本製造工程により得られる乳化組成物は水に触れただけでO/Wエマルションを生じる予備乳化状態にある。以後、該乳化組成物のことを予備乳化物とよぶ。

本発明の製造方法は、下記の工程(I)〜(III)からなる。
工程(I);上記の成分(B)、(C)、(D)をそれぞれ所定量秤取し、成分(B)中に成分(C)、(D)を汎用ミキサーによる攪拌を行いながら、溶解させ均質化させる。
工程(II);引き続きミキサーによる攪拌を行いながら上記の成分(A)を徐々に添加する。
工程(III);工程(II)で得られた組成物は高粘性ゲルの性状をしており、気泡を噛み込んでいることから、真空ポンプに接続した密閉容器中にて空気を除いた。
Next, a method for producing the emulsion composition of the present invention will be described.
The emulsified composition obtained by this production process is in a pre-emulsified state where an O / W emulsion is produced simply by touching water. Hereinafter, the emulsified composition is referred to as a preliminary emulsion.

The production method of the present invention comprises the following steps (I) to (III).
Step (I): The above components (B), (C), and (D) are weighed in predetermined amounts, and the components (C) and (D) are stirred into the component (B) using a general-purpose mixer. Dissolve and homogenize.
Step (II): Subsequently, the above component (A) is gradually added while stirring with a mixer.
Step (III): The composition obtained in Step (II) is in the form of a highly viscous gel and has air bubbles in it, so air was removed in a sealed container connected to a vacuum pump.

特性、用途
本発明の予備乳化組成物は、水もしくは消化液と接触すると速やかに乳化・分散する自己乳化性に優れたものであり、難水溶性物質の吸収性改善に寄与する。本発明で得られる予備乳化組成物は、そのまま水等の水性液体に添加し溶かし、摂取することも出来るが、軟カプセルに封入することにより軟カプセル製剤として用いることができる。その場合、水等の水性液体もしくは生体内の水分によって軟カプセルの皮膜が崩壊し、次いで内容物がO/Wエマルションを形成する。
本発明の予備乳化組成物は、乳化剤配合量が少なくて済み、油性成分比率が高くなる分、生理活性物質などの脂溶性有効成分を多く封入したソフトカプセル剤を提供することが可能である。
本発明の乳化組成物は、ソフトカプセル被膜を軟化、変形させることが無く、ソフトカプセル剤の安定性が向上する。
また、熱安定性が高く、保管中に60℃程度の高温になっても薬液中から油性成分が分離しないので、保存性にも優れている。
そして本発明は、乳化組成物をソフトカプセルに充填して得られるソフトカプセル製剤並びにこれらを含む健康食品、医薬品、医薬部外品、化粧品に適する。生理活性物質などの脂溶性有効成分含有比率が高いので、少量の摂取で済む生理活性物質に対しては、ソフトカプセルの小型化が可能となり、小児や高齢者にとって、飲み下しの改善となる。
Characteristics and Uses The pre-emulsified composition of the present invention has excellent self-emulsifying properties that quickly emulsify and disperse when contacted with water or digestive fluid, and contributes to improving the absorbability of poorly water-soluble substances. The pre-emulsified composition obtained in the present invention can be added to an aqueous liquid such as water as it is, dissolved, and ingested, but can be used as a soft capsule preparation by encapsulating in a soft capsule. In that case, the film of the soft capsule is collapsed by an aqueous liquid such as water or moisture in the living body, and then the content forms an O / W emulsion.
The pre-emulsified composition of the present invention requires only a small amount of the emulsifier and can provide a soft capsule encapsulating a large amount of a fat-soluble active ingredient such as a physiologically active substance as the oil component ratio increases.
The emulsified composition of the present invention does not soften or deform the soft capsule film and improves the stability of the soft capsule.
In addition, it has high thermal stability, and even when it reaches a high temperature of about 60 ° C. during storage, it does not separate the oil component from the chemical solution, so it has excellent storage stability.
The present invention is suitable for soft capsule preparations obtained by filling an emulsified composition into soft capsules, and health foods, pharmaceuticals, quasi drugs and cosmetics containing these. Since the content ratio of fat-soluble active ingredients such as physiologically active substances is high, it is possible to reduce the size of soft capsules for physiologically active substances that only require a small amount of intake, which improves the swallowing for children and the elderly.

次に、本発明を実施例によりさらに詳細に説明するが、本発明はこれらの例によってなんら限定されるものではない。

試験例
難溶性生理活性成分を含まない溶媒として油剤のみを使用して予備乳化物を作成した試験例である。試験液の調製は表1の組成に基づき行った。まず、リゾレシチン(辻製油(株) SLP LPC-70 リゾホスファチジルコリン濃度65%以上)を所定量秤取し、グリセリン(和光純薬工業(株)試薬特級 グリセリン)、ソルビトール、水からなる多価アルコール相に添加し、直径120mmのディスクタービンを取り付けた汎用攪拌機(新東科学(株) HEIDONスリーワンモーターBL1200)にて500rpm速度で攪拌を行いながら、これらを多価アルコール中に溶解させた。完全に均一になったことを確認した後、引き続き攪拌を行いながら、油性成分として食用精製魚油(DHA含有魚油(タマ生化学(株) DHA-46FII)あるいは中鎖脂肪酸トリグリセライド(花王(株)ココナードRK)を先の多価アルコール相中へ徐々に添加し、予備乳化物を得た。その後、高粘性ゲル中に含まれる気泡を真空ポンプに接続した密閉容器中にて除き、最終的な予備乳化物を得た。
EXAMPLES Next, although an Example demonstrates this invention further in detail, this invention is not limited at all by these examples.

Test example
This is a test example in which a pre-emulsion was prepared using only an oil agent as a solvent not containing a hardly soluble bioactive component. The test solution was prepared based on the composition shown in Table 1. First, a predetermined amount of lysolecithin (Sakai Oil Co., Ltd. SLP LPC-70 lysophosphatidylcholine concentration of 65% or more) is weighed and a polyhydric alcohol phase consisting of glycerin (Wako Pure Chemical Industries, Ltd. reagent grade glycerin), sorbitol and water. These were dissolved in polyhydric alcohol while stirring at 500 rpm with a general-purpose stirrer (Shinto Kagaku Co., Ltd. HEIDON Three-One Motor BL1200) equipped with a disk turbine having a diameter of 120 mm. After confirming that it was completely uniform, edible refined fish oil (DHA-containing fish oil (THA Seikagaku Co., Ltd. DHA-46FII) or medium-chain fatty acid triglyceride (Kao Co., Ltd., Cocoonado) RK) was gradually added into the polyhydric alcohol phase to obtain a pre-emulsion, and then the bubbles contained in the high-viscosity gel were removed in a sealed container connected to a vacuum pump to obtain a final pre-emulsion. An emulsion was obtained.

Figure 2011012003
Figure 2011012003

表2の通り、比較例として、グリセリンとソルビトールの比率を変化させたものを実施例と同様の方法で作成し評価を行った。   As Table 2, as a comparative example, what changed the ratio of glycerol and sorbitol was created and evaluated by the same method as the Example.

Figure 2011012003
Figure 2011012003

得られた予備乳化物の評価方法を以下に示す。

<予備乳化物の初期安定性>
予備乳化物の調製直後の初期安定性を目視観察により判断した。予備乳化物の状態を以下のように評価した。
○:油が多価アルコール相から分離することなく予備乳化物を形成したもの
△:油が多価アルコール相表面に染み出しているもの
×:油が多価アルコール相から完全に分離
このうち、評価が○のものを合格とした。
The evaluation method of the obtained preliminary emulsion is shown below.

<Initial stability of preliminary emulsion>
The initial stability immediately after preparation of the preliminary emulsion was judged by visual observation. The state of the preliminary emulsion was evaluated as follows.
○: The oil formed a pre-emulsion without separating from the polyhydric alcohol phase. Δ: The oil exuded on the surface of the polyhydric alcohol phase. X: The oil was completely separated from the polyhydric alcohol phase. The evaluation was ○.

<予備乳化物の水分、水分活性測定>
得られた予備乳化物については、脱泡後2〜3%程度の水分を失うことから、参考値としてカールフィッシャー水分計(京都電子工業(株)MKS-1S)による水分測定を行った。
<Measurement of water content and water activity of pre-emulsion>
About the obtained pre-emulsion, since about 2-3% of water | moisture content is lost after defoaming, the water | moisture content measurement by the Karl Fischer moisture meter (Kyoto Electronics Industry Co., Ltd. MKS-1S) was performed as a reference value.

<予備乳化物の粘度評価>
B型粘度計(ローター No.4、回転数12)による粘度測定(25℃)を実施し、測定開始後10回転目における粘度を読み取った。得られた粘度を以下のように評価した。
◎:3.0×104mPa・s未満 (流動性優)
○:3.0×104mPa・s以上、5.0×104mPa・s未満(流動性良)
×:5.0×104mPa・s以上(流動性無し、充填不可能)
このうち、○以上のものを合格とした。
<Viscosity evaluation of preliminary emulsion>
Viscosity measurement (25 ° C.) was performed with a B-type viscometer (rotor No. 4, rotation speed 12), and the viscosity at the 10th rotation after reading was measured. The resulting viscosity was evaluated as follows.
A: Less than 3.0 × 10 4 mPa · s (excellent fluidity)
○: 3.0 × 10 4 mPa · s or more, less than 5.0 × 10 4 mPa · s (good fluidity)
×: 5.0 × 10 4 mPa · s or more (no fluidity, unfillable)
Among these, the ones with ◯ or higher were regarded as acceptable.

<自己乳化性の評価方法>
本発明で得られた乳化組成物の自己乳化性は、水と接触させた際の分散性によって評価した。具体的にはビーカーに入れた37℃のミリQ水200mLに対して、100μLの試料を滴下したときの状態を以下のように評価した。
○:1mm以上の油滴を気-液界面に形成しないもの。
△:油滴同士が凝集・合一し、1mm以上の油滴を気-液界面に形成してしまうもの。
×:全く自己乳化しないもの。
このうち、評価が○のものを合格とした。
また評価は、ソフトカプセル充填前とソフトカプセル充填後(乾燥後)の2度評価を行った。
<Self-emulsifying evaluation method>
The self-emulsifying property of the emulsified composition obtained in the present invention was evaluated by the dispersibility when contacted with water. Specifically, the state when a 100 μL sample was dropped into 200 mL of 37 ° C. milliQ water placed in a beaker was evaluated as follows.
○: Oil droplets with a diameter of 1 mm or more are not formed at the gas-liquid interface.
Δ: Oil droplets aggregate and coalesce to form oil droplets of 1 mm or more at the gas-liquid interface.
X: What does not self-emulsify at all.
Among these, the ones with an evaluation of ◯ were regarded as passing.
Evaluation was performed twice before soft capsule filling and after soft capsule filling (after drying).

<軟カプセルの変形試験評価方法>
本発明で得られた乳化組成物を軟カプセルに充填した際のカプセル皮膜安定性をカプセル変形量から評価した。具体的には、得られた軟カプセル製剤をアルミ包装に入れ、40℃75%RH環境下で保管し、8週間後の軟カプセルの短径方向長さをノギスで測定することで、以下のように評価した。
○:変形量が0mm以上0.5mm未満
△:変形量が0.5mm以上1.0mm未満
×:変形量が1.0mm以上
このうち、評価が○のものを合格とした。
<Method for evaluating deformation test of soft capsule>
Capsule film stability when soft capsules were filled with the emulsion composition obtained in the present invention was evaluated from the amount of capsule deformation. Specifically, the obtained soft capsule preparation is put in an aluminum package and stored in an environment of 40 ° C. and 75% RH, and the length of the soft capsule in the short diameter direction after 8 weeks is measured with a caliper. It was evaluated as follows.
○: Deformation amount of 0 mm or more and less than 0.5 mm △: Deformation amount of 0.5 mm or more and less than 1.0 mm ×: Deformation amount of 1.0 mm or more

実施例1〜4の評価結果を各配合成分組成と共に表3に示す。また、比較例1〜7の評価結果を各配合成分組成とともに表4に示す。   The evaluation results of Examples 1 to 4 are shown in Table 3 together with the respective composition components. Moreover, the evaluation result of Comparative Examples 1-7 is shown in Table 4 with each compounding component composition.

Figure 2011012003
Figure 2011012003

Figure 2011012003
Figure 2011012003

表3に示すように、実施例1〜4は、粘度が50000mPa未満であり、充填に適切な粘度を有し、かつ、自己乳化性結果が良好であった。これらの試験例の総合評価は、○であった。   As shown in Table 3, Examples 1 to 4 had a viscosity of less than 50000 mPa, an appropriate viscosity for filling, and good self-emulsifying results. The overall evaluation of these test examples was ○.

表4は、比較例の結果である。比較例1〜3は、粘度及び自己乳化性は良好であったが、ソフトカプセル皮膜への内溶液移行によりソフトカプセルの変形が認められた。また、比較例4については、粘度が100000mPa以上の高粘度であり、×であった。比較例5は調製過程で油の分離が確認されたことから調製不可と判断し、評価対象外とした。比較例6、7は粘度及び自己乳化性は良好であったが、ソフトカプセル皮膜への内溶液移行によりソフトカプセルの変形が認められた。
なお、比較例1〜3は、液状多価アルコール(B1):固体状多価アルコール(B2)の比が、1:1.4〜1.9であった。比較例4は液状多価アルコール(B1)が配合されなかった。比較例5〜7固体状多価アルコールが配合されなかった。これらの総合評価は、ソフトカプセルの変形のため、×であった。
Table 4 shows the results of the comparative example. In Comparative Examples 1 to 3, the viscosity and the self-emulsifying property were good, but deformation of the soft capsule was observed due to transfer of the inner solution to the soft capsule film. Moreover, about the comparative example 4, the viscosity was 100000 mPa or more high viscosity, and was x. In Comparative Example 5, it was judged that preparation was impossible because separation of oil was confirmed in the preparation process, and it was excluded from evaluation. In Comparative Examples 6 and 7, the viscosity and self-emulsification were good, but deformation of the soft capsule was observed due to the transfer of the inner solution to the soft capsule film.
In Comparative Examples 1 to 3, the ratio of liquid polyhydric alcohol (B1): solid polyhydric alcohol (B2) was 1: 1.4 to 1.9. In Comparative Example 4, the liquid polyhydric alcohol (B1) was not blended. Comparative Examples 5-7 Solid polyhydric alcohol was not blended. These comprehensive evaluations were x due to the deformation of the soft capsule.

このように、本発明のソフトカプセル製剤用予備乳化剤は、粘度が低減し、かつ、充填後のカプセル製剤の変形が抑制されることが示された。   Thus, it was shown that the pre-emulsifier for a soft capsule formulation of the present invention has a reduced viscosity and suppresses deformation of the capsule formulation after filling.

Claims (10)

油性成分(A)、多価アルコール(B)、乳化剤(C)を含有するソフトカプセル製剤用乳化組成物であって、
多価アルコール(B)が無水状態で液状の多価アルコール(B−1)と固体状の多価アルコール(B−2)を含有し、B−1とB−2の比が、1:3〜1:6であることを特徴とするソフトカプセル製剤用乳化組成物。
An emulsified composition for a soft capsule formulation containing an oily component (A), a polyhydric alcohol (B), and an emulsifier (C),
The polyhydric alcohol (B) contains a liquid polyhydric alcohol (B-1) and a solid polyhydric alcohol (B-2) in an anhydrous state, and the ratio of B-1 to B-2 is 1: 3. An emulsified composition for soft capsule preparations, characterized in that it is ˜1: 6.
水を除く組成物中の多価アルコール(B)が15〜25%重量、乳化剤(C)が2.0%重量以下、油性成分(A)が65.0〜80.0%重量であることを特徴とする請求項1記載のソフトカプセル製剤用乳化組成物。 The polyhydric alcohol (B) in the composition excluding water is 15 to 25% by weight, the emulsifier (C) is 2.0% by weight or less, and the oil component (A) is 65.0 to 80.0% by weight. 2. The emulsified composition for soft capsule preparations according to 1. 油性成分(A)が中鎖脂肪酸トリグリセライドまたは動植物性オイルであり、当該油性成分に可溶な脂溶性物質(D)を含む請求項1又は2記載のソフトカプセル製剤用乳化組成物。 The emulsified composition for a soft capsule preparation according to claim 1 or 2, wherein the oil component (A) is a medium-chain fatty acid triglyceride or an animal or vegetable oil and contains a fat-soluble substance (D) soluble in the oil component. 多価アルコールB−1がグリセリンであることを特徴とする請求項1〜3のいずれかに記載のソフトカプセル製剤用乳化組成物。 Polyhydric alcohol B-1 is glycerol, The emulsion composition for soft capsule formulations in any one of Claims 1-3 characterized by the above-mentioned. 多価アルコールB−2がD-ソルビトール及び/又は還元澱粉糖化物であることを特徴とする請求項1〜4のいずれかに記載のソフトカプセル製剤用乳化組成物。 The emulsion composition for soft capsule preparation according to any one of claims 1 to 4, wherein the polyhydric alcohol B-2 is D-sorbitol and / or a reduced starch saccharified product. 乳化剤(C)がリゾレシチンであり、原料中に含まれるリゾホスファチジルコリンの濃度が少なくとも18%以上、望ましくは65%以上であることを特徴とする請求項1〜5のいずれかに記載のソフトカプセル製剤用乳化組成物。 The emulsifier (C) is lysolecithin, and the concentration of lysophosphatidylcholine contained in the raw material is at least 18% or more, preferably 65% or more, for soft capsule preparations according to any one of claims 1 to 5 Emulsified composition. 油性成分に可溶な脂溶性物質(D)が、コエンザイムQ10、還元型コエンザイムQ10、リポ酸、α、β-、γ-δ-トコフェロール、α、β-、γ-δ-トコトリエノール、α、β-、γ-δ-カロテン、リコペン、ルテイン、ゼアキサンチン、アスタキサンチン、ビタミンD、ビタミンA、ビタミンP、DHA、EPA、スクワランから選ばれる少なくとも1種または2種以上を含むことを特徴とする請求項1〜7のいずれかに記載のソフトカプセル製剤用乳化組成物。 The fat-soluble substance (D) soluble in the oil component is coenzyme Q10, reduced coenzyme Q10, lipoic acid, α, β-, γ-δ-tocopherol, α, β-, γ-δ-tocotrienol, α, β 2. It comprises at least one or more selected from-, γ-δ-carotene, lycopene, lutein, zeaxanthin, astaxanthin, vitamin D, vitamin A, vitamin P, DHA, EPA, and squalane. The emulsion composition for soft capsule formulations in any one of -7. 請求項1〜7のいずれかに記載されたソフトカプセル製剤用乳化組成物を封入したソフトカプセル製剤。 The soft capsule formulation which enclosed the emulsion composition for soft capsule formulations in any one of Claims 1-7. ソフトカプセル封入前の水が10重量%以下であり、カプセルに封入後、内溶液中に含まれる水を乾燥工程で5%以下にしたことを特徴とする請求項1〜7のいずれかに記載されたソフトカプセル製剤用乳化組成物を封入したソフトカプセル製剤。 The water before encapsulating the soft capsule is 10% by weight or less, and after encapsulating in the capsule, the water contained in the inner solution is 5% or less in the drying step. Soft capsule preparation encapsulating an emulsified composition for soft capsule preparation. 油性成分(A)、多価アルコール(B)、乳化剤(C)を含有するソフトカプセル製剤用乳化組成物であって、多価アルコール(B)が無水状態で液状の多価アルコール(B−1)と固体状の多価アルコール(B−2)を含有し、B−1とB−2の比が、1:3〜1:6であるソフトカプセル製剤用乳化組成物を調整する方法であって、
乳化剤(C)を多価アルコール(B)に溶かし込み、次いで、均質に攪拌しつつ油性成分(A)を徐々に加えて高粘性ゲルを調製し、脱泡してソフトカプセル製剤用乳化組成物を調整する方法。
An emulsified composition for a soft capsule formulation comprising an oily component (A), a polyhydric alcohol (B), and an emulsifier (C), wherein the polyhydric alcohol (B) is liquid in an anhydrous state. And a solid polyhydric alcohol (B-2), and the ratio of B-1 and B-2 is 1: 3 to 1: 6.
The emulsifier (C) is dissolved in the polyhydric alcohol (B), and then the oily component (A) is gradually added while stirring uniformly to prepare a highly viscous gel, which is defoamed to obtain an emulsified composition for a soft capsule formulation. How to adjust.
JP2009156744A 2009-07-01 2009-07-01 Emulsified composition for soft capsule and soft capsule Active JP5421674B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009156744A JP5421674B2 (en) 2009-07-01 2009-07-01 Emulsified composition for soft capsule and soft capsule

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009156744A JP5421674B2 (en) 2009-07-01 2009-07-01 Emulsified composition for soft capsule and soft capsule

Publications (2)

Publication Number Publication Date
JP2011012003A true JP2011012003A (en) 2011-01-20
JP5421674B2 JP5421674B2 (en) 2014-02-19

Family

ID=43591251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009156744A Active JP5421674B2 (en) 2009-07-01 2009-07-01 Emulsified composition for soft capsule and soft capsule

Country Status (1)

Country Link
JP (1) JP5421674B2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013031949A1 (en) * 2011-09-02 2013-03-07 富士フイルム株式会社 Soft capsule pharmaceutical preparation, composition for soft capsule pharmaceutical preparation, and method for producing soft capsule pharmaceutical preparation
JP2013049656A (en) * 2011-08-31 2013-03-14 Fujifilm Corp Soft capsule preparation and method for producing the same
CN103238833A (en) * 2012-02-01 2013-08-14 株式会社芳珂 Composition containing stabilized coenzyme q10 at high concentration
JP2015007008A (en) * 2013-06-25 2015-01-15 アール.ピー. シェーラー テクノロジーズ エルエルシー Shell formation composition for soft capsules, and soft capsule
WO2015008849A1 (en) 2013-07-18 2015-01-22 持田製薬株式会社 Self-emulsifying composition of ω-3 fatty acid
WO2015008848A1 (en) 2013-07-18 2015-01-22 持田製薬株式会社 SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
JP2017509699A (en) * 2014-03-21 2017-04-06 ガットフォッセ ホールディング An anhydrous consumable device for the immediate preparation of a single dose cosmetic composition
KR20170103836A (en) 2015-01-21 2017-09-13 모치다 세이야쿠 가부시키가이샤 Self-emulsifying composition of? 3 fatty acid
JP2017186320A (en) * 2016-03-30 2017-10-12 富士フイルム株式会社 Emulsified composition and soft capsule formulation containing the same
CN109288050A (en) * 2017-12-01 2019-02-01 天津地天科技发展有限公司 A kind of three kinds of composition of raw materials and its manufacture craft of Amti-sanility health-care food and food
KR20190143213A (en) * 2018-06-20 2019-12-30 코스맥스바이오 주식회사 Slurry soft gel capsule suspension agent and slurry soft gel capsule containing the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014188861A1 (en) 2013-05-20 2014-11-27 ユーハ味覚糖株式会社 Gel-like composition having high ubiquinol content

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61500432A (en) * 1982-12-09 1986-03-13 ビルトン,ジエラルド エル. Easily absorbable fatty acid emulsion
WO1991012821A1 (en) * 1990-03-02 1991-09-05 Shiseido Company, Ltd. Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic
JPH0559391A (en) * 1991-08-30 1993-03-09 Mitsui & Co Ltd Method for producing purified propolis and purified propolis component-containing o/w type emulsion
JPH07256085A (en) * 1993-10-29 1995-10-09 L'oreal Sa Water-in-oil emulsion containing polyol and cosmetic composition containing the same
JPH092988A (en) * 1995-06-21 1997-01-07 Kao Corp Glyceryl etherified polyhydric alcohol and its production
JPH10273436A (en) * 1997-03-31 1998-10-13 Tokai Capsule Kk Soft capsule for chewing
JP2003238396A (en) * 2002-02-21 2003-08-27 Nisshin Pharma Inc Coenzyme Q10-containing emulsion composition
JP2003300870A (en) * 2002-02-08 2003-10-21 Kyowa Hai Foods Kk Ubiquinone-containing water-soluble composition
JP2006056816A (en) * 2004-08-19 2006-03-02 Nof Corp Pre-emulsion containing fat-soluble vitamins
WO2009004999A1 (en) * 2007-06-29 2009-01-08 Takeda Pharmaceutical Company Limited Seamless capsule
JP2009114157A (en) * 2007-10-19 2009-05-28 Fancl Corp Emulsion composition for capsule

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61500432A (en) * 1982-12-09 1986-03-13 ビルトン,ジエラルド エル. Easily absorbable fatty acid emulsion
WO1991012821A1 (en) * 1990-03-02 1991-09-05 Shiseido Company, Ltd. Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic
JPH0559391A (en) * 1991-08-30 1993-03-09 Mitsui & Co Ltd Method for producing purified propolis and purified propolis component-containing o/w type emulsion
JPH07256085A (en) * 1993-10-29 1995-10-09 L'oreal Sa Water-in-oil emulsion containing polyol and cosmetic composition containing the same
JPH092988A (en) * 1995-06-21 1997-01-07 Kao Corp Glyceryl etherified polyhydric alcohol and its production
JPH10273436A (en) * 1997-03-31 1998-10-13 Tokai Capsule Kk Soft capsule for chewing
JP2003300870A (en) * 2002-02-08 2003-10-21 Kyowa Hai Foods Kk Ubiquinone-containing water-soluble composition
JP2003238396A (en) * 2002-02-21 2003-08-27 Nisshin Pharma Inc Coenzyme Q10-containing emulsion composition
JP2006056816A (en) * 2004-08-19 2006-03-02 Nof Corp Pre-emulsion containing fat-soluble vitamins
WO2009004999A1 (en) * 2007-06-29 2009-01-08 Takeda Pharmaceutical Company Limited Seamless capsule
JP2009114157A (en) * 2007-10-19 2009-05-28 Fancl Corp Emulsion composition for capsule

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013049656A (en) * 2011-08-31 2013-03-14 Fujifilm Corp Soft capsule preparation and method for producing the same
EP2752202A4 (en) * 2011-09-02 2015-04-15 Fujifilm Corp Soft capsule pharmaceutical preparation, composition for soft capsule pharmaceutical preparation, and method for producing soft capsule pharmaceutical preparation
JP2013063970A (en) * 2011-09-02 2013-04-11 Fujifilm Corp Soft capsule preparation, composition for soft capsule preparation, and method for producing soft capsule preparation
CN103732255A (en) * 2011-09-02 2014-04-16 富士胶片株式会社 Soft capsule pharmaceutical preparation, composition for soft capsule pharmaceutical preparation, and method for producing soft capsule pharmaceutical preparation
WO2013031949A1 (en) * 2011-09-02 2013-03-07 富士フイルム株式会社 Soft capsule pharmaceutical preparation, composition for soft capsule pharmaceutical preparation, and method for producing soft capsule pharmaceutical preparation
CN103238833A (en) * 2012-02-01 2013-08-14 株式会社芳珂 Composition containing stabilized coenzyme q10 at high concentration
JP2015007008A (en) * 2013-06-25 2015-01-15 アール.ピー. シェーラー テクノロジーズ エルエルシー Shell formation composition for soft capsules, and soft capsule
US9814683B2 (en) 2013-06-25 2017-11-14 R.P. Scherer Technologies, Llc Shell-forming compositions for soft capsules and soft capsules
CN110840874A (en) * 2013-07-18 2020-02-28 持田制药株式会社 Self-emulsifying compositions of omega-3 fatty acids
CN105530927A (en) * 2013-07-18 2016-04-27 持田制药株式会社 Self-emulsifying compositions of omega-3 fatty acids
KR20160032120A (en) 2013-07-18 2016-03-23 모치다 세이야쿠 가부시키가이샤 Self-emulsifying composition of ω-3 fatty acid
US9801843B2 (en) 2013-07-18 2017-10-31 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of ω3 fatty acid
WO2015008848A1 (en) 2013-07-18 2015-01-22 持田製薬株式会社 SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
EP3763364A1 (en) 2013-07-18 2021-01-13 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of omega-3 fatty acid
WO2015008849A1 (en) 2013-07-18 2015-01-22 持田製薬株式会社 Self-emulsifying composition of ω-3 fatty acid
EP3735963A1 (en) 2013-07-18 2020-11-11 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of omega-3 fatty acid
JP2017509699A (en) * 2014-03-21 2017-04-06 ガットフォッセ ホールディング An anhydrous consumable device for the immediate preparation of a single dose cosmetic composition
US10786575B2 (en) 2015-01-21 2020-09-29 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of Ω3 fatty acid
KR20170103836A (en) 2015-01-21 2017-09-13 모치다 세이야쿠 가부시키가이샤 Self-emulsifying composition of? 3 fatty acid
KR20210158422A (en) 2015-01-21 2021-12-30 모치다 세이야쿠 가부시키가이샤 SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
US10758622B2 (en) 2015-01-21 2020-09-01 Mochida Pharmaceuticals Co., Ltd. Self-emulsifying composition of omega-3 fatty acid
JP2017186320A (en) * 2016-03-30 2017-10-12 富士フイルム株式会社 Emulsified composition and soft capsule formulation containing the same
CN109288050A (en) * 2017-12-01 2019-02-01 天津地天科技发展有限公司 A kind of three kinds of composition of raw materials and its manufacture craft of Amti-sanility health-care food and food
KR102133837B1 (en) 2018-06-20 2020-07-14 코스맥스바이오 주식회사 Slurry soft gel capsule suspension agent and slurry soft gel capsule containing the same
KR20190143213A (en) * 2018-06-20 2019-12-30 코스맥스바이오 주식회사 Slurry soft gel capsule suspension agent and slurry soft gel capsule containing the same

Also Published As

Publication number Publication date
JP5421674B2 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
JP5421674B2 (en) Emulsified composition for soft capsule and soft capsule
JP5820256B2 (en) Self-emulsifying formulation
JP5380134B2 (en) Emulsified composition for soft capsule and soft capsule
TWI222880B (en) A novel drug delivery system: formulation for fat-soluble drugs
TWI531318B (en) Microemulsion preconcentrate and microemulsion and preparation method thereof
JP2015522031A (en) Racecadotril lipid composition
KR20130089196A (en) Composition containing stabilized coenzyme q10 at high concentration
JP4312423B2 (en) Enteric capsule
JP7372714B1 (en) Water-filled capsule and its manufacturing method
JP2009114157A (en) Emulsion composition for capsule
JP5738721B2 (en) Soft capsule preparation and method for producing the same
EP2752202B1 (en) Soft capsule pharmaceutical preparation, composition for soft capsule pharmaceutical preparation, and method for producing soft capsule pharmaceutical preparation
JP2019206518A (en) Oil and fat-containing composition and oral preparation
JP6533003B1 (en) Carotene-containing oily composition
JP5847475B2 (en) Oil-containing composition and oral preparation containing the same
CN111346087B (en) Oily composition containing vitamin E
JP2019085349A (en) Composition for oral intake containing poorly soluble substance, method for improving digestive tract absorbability of poorly soluble substance, and method for stabilizing in the stomach emulsion of oil-in-water emulsion containing poorly soluble substance
JP7563813B2 (en) Water-filled capsule and method for producing same
JP5283654B2 (en) Filling composition for soft capsules
JP5869764B2 (en) Capsule filling composition
JP2020083806A (en) Vitamin E-containing oily composition
JP2020002057A (en) Self-emulsifiable composition comprising geranylgeraniol
KR20240077381A (en) Composition for increasing absorption of fat-soluble physiologically active ingredients using self-emulsifying delivery system
JP2005074303A (en) Dispersion liquid composition for use in filling capsule, filling composition and capsule agent
WO2024096059A1 (en) Water-filled capsule and manufacturing method thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131122

R150 Certificate of patent or registration of utility model

Ref document number: 5421674

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250